Government-Owned Inventions; Availability for Licensing, 50858-50859 [2015-20694]
Download as PDF
<![CDATA[
50858
Federal Register / Vol. 80, No. 162 / Friday, August 21, 2015 / Notices
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 30, 2015.
Valery Gheen,
NHLBI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2015–20708 Filed 8–20–15; 8:45 am]
BILLING CODE 4140–01–P
Dated: August 17, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2015–20644 Filed 8–20–15; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
rmajette on DSK7SPTVN1PROD with NOTICES
National Cancer Institute; Notice of
Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Cancer
Institute Special Emphasis Panel; Jun2015
Cycle 20 NExT SEP Committee Meeting.
Date: September 22, 2015.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Campus Building 31,
Conference Room 6C6, Bethesda, MD 20892.
Contact Person: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20817,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, MD 20850, (240) 276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
VerDate Sep<11>2014
15:07 Aug 20, 2015
Jkt 235001
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
SUMMARY:
Novel Benztropine Analogs for
Treatment of Cocaine Abuse and Other
Mental Disorders
Description of Technology: Dopamine
is a neurotransmitter that exerts
important effects on locomotor activity,
motivation and reward, and cognition.
The dopamine transporter (DAT) is
expressed on the plasma membrane of
dopamine synthesizing neurons, and is
responsible for clearing dopamine
released into the extra-cellular space,
thereby regulating neurotransmission.
The dopamine transporter plays a
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
significant role in neurotoxicity and
human diseases, such as Parkinson’s
disease, drug abuse (especially cocaine
addiction), Attention Deficit Disorder/
Attention Deficit Hyperactivity Disorder
(ADD/ADHD), and a number of other
CNS disorders. Therefore, the dopamine
transporter is a strong target for research
and the discovery of potential
therapeutics for the treatment of these
indications.
This invention discloses novel
benztropine analogs and methods of
using these analogs for treatment of
mental and conduct disorders such as
cocaine abuse, narcolepsy, ADHD,
obesity and nicotine abuse. The
disclosed analogs are highly selective
and potent inhibitors of DAT, but
without an apparent cocaine-like
behavioral profile. In addition to their
use as a treatment for cocaine abuse,
these compounds have also shown
efficacy in animal models of ADHD and
nicotine abuse, and have also been
shown to reduce food intake in animals.
They may also be useful medications for
other indications where dopaminerelated behavior is compromised, such
as alcohol addiction, tobacco addiction,
and Parkinson’s disease.
Potential Commercial Applications:
• Drug leads for treatment of cocaine
abuse, ADHD, nicotine abuse, obesity,
and other dopamine-related disorders
• Imaging probes for dopamine
transporter binding sites
Development Stage: Early-stage; In
vitro data available
Inventors: Amy H. Newman, Mu-fa
Zou, Jonathan L. Katz (all of NIDA)
Intellectual Property: HHS Reference
No. E–234–2005/1—US Patent No.
8,383,817 issued February 26, 2013
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565; tongb@
mail.nih.gov
Collaborative Research Opportunity:
The National Institute on Drug Abuse,
Medicinal Chemistry and Psychobiology
Sections, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize medications to treat
cocaine abuse and addiction. For
collaboration opportunities please
contact John D. Hewes, Ph.D. at
john.hewes@nih.gov.
Novel Dopamine Receptor Ligands as
Therapeutics for Central Nervous
System Disorders
Description of Technology: The
dopamine D3 receptor subtype is a
member of the dopamine D2 subclass of
receptors. These receptors have been
implicated in a number of CNS
disorders, including psychostimulant
E:\FR\FM\21AUN1.SGM
21AUN1
rmajette on DSK7SPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 162 / Friday, August 21, 2015 / Notices
abuse, psychosis and Parkinson’s
disease. Compounds that bind with high
affinity and selectivity to D3 receptors
can not only provide important tools
with which to study the structure and
function of this receptor subtype, but
may also have therapeutic potential in
the treatment of numerous psychiatric
and neurologic disorders.
The 4-phenylpiperazine derivatives
are an important class of dopamine D3
selective ligands. However, due to their
highly lipophilic nature, these
compounds suffer from solubility
problems in aqueous media and reduced
bioavailability. To address this problem,
a process was designed to introduce
functionality into the carbon chain
linker of these compounds. Compared to
currently available dopamine D3
receptor ligands, the resulting
compounds show improved
pharmacological properties and D3
selectivities but due to their more
hydrophilic nature, these derivatives are
predicted to have improved water
solubility and bioavailability.
Potential Commercial Applications:
• Therapeutics for a variety of
psychiatric and neurologic disorders
• Research tools to study D3 receptor
structure and function
Competitive Advantages:
• Improved pharmacological
properties and selectivity over existing
dopamine D3 receptor ligands
• Hydrophilic nature likely to lead to
improved water solubility and
bioavailability
Development Stage: Early-stage; In
vitro data available
Inventors: Amy H. Newman (NIDA),
Peter Grundt (NIDA), Jianjing Cao
(NIDA), Robert Luedtke
Intellectual Property: HHS Reference
No. E–128–2006/0—US Patent No.
8,748,608 issued June 10, 2014
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565; tongb@
mail.nih.gov
Collaborative Research Opportunity:
The National Institute on Drug Abuse,
Medications Discovery Research
Branch, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize 4-phenylpiperazine
derivatives as dopamine D3 selective
ligands. For collaboration opportunities,
please contact Vio Conley, M.S. at 240–
276–5531 or conleyv@mail.nih.gov.
Genome Wide DNase I Hypersensitive
Sites Detection in Formalin-Fixed
Paraffin-Embedded Single Cells
Description of Technology: A method
of detecting DNase I hypersensitive sites
((DHS) in a single cell or very small
VerDate Sep<11>2014
15:07 Aug 20, 2015
Jkt 235001
number of cells, including cells
recovered from formalin-fixed paraffinembedded (FFPE) tissue slides of
patient samples. DHS has revealed a
large number of potential regulatory
elements for transcriptional regulation
in various cell types. The application of
DNase-Seq techniques to patient
samples can elucidate
pathophysiological mechanisms of gene
function in a variety of diseases as well
as provide potentially important
diagnostic and prognostic information.
Unfortunately, the current DNase-Seq
techniques require large number of cells
and are applicable only to larger
biopsies and surgical specimens. This
technique, called Pico-Seq, allows
detection when only very small
population of cells are available, such as
rare primary tumor cells and
circulating-tumor-cells, isolated by a
variety of methods. Pico-Seq uses
conditions capable of restoring the
DNase I sensitivity, similar to native/
fresh cells, in tissue/cells from slides
processed by extremely harsh
conditions, such as in FFPE tissues.
Potential Commercial Applications:
• Diagnostic and prognostic kits
• Research kits
Competitive Advantages:
• Applicable to very small number of
cells down to a single cell.
• Capable of using cells isolated by
any of the available methods, including
flow cytometry, biopsies, laser capture
microdissection, and even cells
recovered from formalin-fixed paraffinembedded tissue slides of patient
samples.
Development Stage: Early-stage; In
vitro data available
Inventors: Keji Zhao and Tang
Qingsong (NHLBI)
Intellectual Property: HHS Reference
No. E–254–2014/0—US Provisional
Application No. 62/118,574 filed
February 20, 2015
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; ThalhamC@mail.nih.gov
Dated: August 18, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–20694 Filed 8–20–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
50859
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI P01
Meeting II.
Date: October 15–16, 2015.
Time: 8:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Delia Tang, MD, Scientific
Review Officer, Research Programs Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W602, Bethesda, MD
20892, 240–276–6456, tangd@mail.nih.gov
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
I-Transition to Independence.
Date: October 20–21, 2015.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria Old Town, 1767
King Street, Alexandria, VA 22314.
Contact Person: Sergei Radaev, Ph.D.
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W114, Bethesda, MD 20892, 240–
276–6466, sradaev@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 17, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–20642 Filed 8–20–15; 8:45 am]
National Cancer Institute; Notice of
Closed Meetings
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00041
Fmt 4703
Sfmt 9990
E:\FR\FM\21AUN1.SGM
21AUN1
]]>Agencies
[Federal Register Volume 80, Number 162 (Friday, August 21, 2015)]
[Notices]
[Pages 50858-50859]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-20694]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other
Mental Disorders
Description of Technology: Dopamine is a neurotransmitter that
exerts important effects on locomotor activity, motivation and reward,
and cognition. The dopamine transporter (DAT) is expressed on the
plasma membrane of dopamine synthesizing neurons, and is responsible
for clearing dopamine released into the extra-cellular space, thereby
regulating neurotransmission. The dopamine transporter plays a
significant role in neurotoxicity and human diseases, such as
Parkinson's disease, drug abuse (especially cocaine addiction),
Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder
(ADD/ADHD), and a number of other CNS disorders. Therefore, the
dopamine transporter is a strong target for research and the discovery
of potential therapeutics for the treatment of these indications.
This invention discloses novel benztropine analogs and methods of
using these analogs for treatment of mental and conduct disorders such
as cocaine abuse, narcolepsy, ADHD, obesity and nicotine abuse. The
disclosed analogs are highly selective and potent inhibitors of DAT,
but without an apparent cocaine-like behavioral profile. In addition to
their use as a treatment for cocaine abuse, these compounds have also
shown efficacy in animal models of ADHD and nicotine abuse, and have
also been shown to reduce food intake in animals. They may also be
useful medications for other indications where dopamine-related
behavior is compromised, such as alcohol addiction, tobacco addiction,
and Parkinson's disease.
Potential Commercial Applications:
Drug leads for treatment of cocaine abuse, ADHD, nicotine
abuse, obesity, and other dopamine-related disorders
Imaging probes for dopamine transporter binding sites
Development Stage: Early-stage; In vitro data available
Inventors: Amy H. Newman, Mu-fa Zou, Jonathan L. Katz (all of NIDA)
Intellectual Property: HHS Reference No. E-234-2005/1--US Patent
No. 8,383,817 issued February 26, 2013
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
tongb@mail.nih.gov
Collaborative Research Opportunity: The National Institute on Drug
Abuse, Medicinal Chemistry and Psychobiology Sections, is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
medications to treat cocaine abuse and addiction. For collaboration
opportunities please contact John D. Hewes, Ph.D. at
john.hewes@nih.gov.
Novel Dopamine Receptor Ligands as Therapeutics for Central Nervous
System Disorders
Description of Technology: The dopamine D3 receptor subtype is a
member of the dopamine D2 subclass of receptors. These receptors have
been implicated in a number of CNS disorders, including psychostimulant
[[Page 50859]]
abuse, psychosis and Parkinson's disease. Compounds that bind with high
affinity and selectivity to D3 receptors can not only provide important
tools with which to study the structure and function of this receptor
subtype, but may also have therapeutic potential in the treatment of
numerous psychiatric and neurologic disorders.
The 4-phenylpiperazine derivatives are an important class of
dopamine D3 selective ligands. However, due to their highly lipophilic
nature, these compounds suffer from solubility problems in aqueous
media and reduced bioavailability. To address this problem, a process
was designed to introduce functionality into the carbon chain linker of
these compounds. Compared to currently available dopamine D3 receptor
ligands, the resulting compounds show improved pharmacological
properties and D3 selectivities but due to their more hydrophilic
nature, these derivatives are predicted to have improved water
solubility and bioavailability.
Potential Commercial Applications:
Therapeutics for a variety of psychiatric and neurologic
disorders
Research tools to study D3 receptor structure and function
Competitive Advantages:
Improved pharmacological properties and selectivity over
existing dopamine D3 receptor ligands
Hydrophilic nature likely to lead to improved water
solubility and bioavailability
Development Stage: Early-stage; In vitro data available
Inventors: Amy H. Newman (NIDA), Peter Grundt (NIDA), Jianjing Cao
(NIDA), Robert Luedtke
Intellectual Property: HHS Reference No. E-128-2006/0--US Patent
No. 8,748,608 issued June 10, 2014
Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565;
tongb@mail.nih.gov
Collaborative Research Opportunity: The National Institute on Drug
Abuse, Medications Discovery Research Branch, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize 4-
phenylpiperazine derivatives as dopamine D3 selective ligands. For
collaboration opportunities, please contact Vio Conley, M.S. at 240-
276-5531 or conleyv@mail.nih.gov.
Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed
Paraffin-Embedded Single Cells
Description of Technology: A method of detecting DNase I
hypersensitive sites ((DHS) in a single cell or very small number of
cells, including cells recovered from formalin-fixed paraffin-embedded
(FFPE) tissue slides of patient samples. DHS has revealed a large
number of potential regulatory elements for transcriptional regulation
in various cell types. The application of DNase-Seq techniques to
patient samples can elucidate pathophysiological mechanisms of gene
function in a variety of diseases as well as provide potentially
important diagnostic and prognostic information. Unfortunately, the
current DNase-Seq techniques require large number of cells and are
applicable only to larger biopsies and surgical specimens. This
technique, called Pico-Seq, allows detection when only very small
population of cells are available, such as rare primary tumor cells and
circulating-tumor-cells, isolated by a variety of methods. Pico-Seq
uses conditions capable of restoring the DNase I sensitivity, similar
to native/fresh cells, in tissue/cells from slides processed by
extremely harsh conditions, such as in FFPE tissues.
Potential Commercial Applications:
Diagnostic and prognostic kits
Research kits
Competitive Advantages:
Applicable to very small number of cells down to a single
cell.
Capable of using cells isolated by any of the available
methods, including flow cytometry, biopsies, laser capture
microdissection, and even cells recovered from formalin-fixed paraffin-
embedded tissue slides of patient samples.
Development Stage: Early-stage; In vitro data available
Inventors: Keji Zhao and Tang Qingsong (NHLBI)
Intellectual Property: HHS Reference No. E-254-2014/0--US
Provisional Application No. 62/118,574 filed February 20, 2015
Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301-
435-4507; ThalhamC@mail.nih.gov
Dated: August 18, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-20694 Filed 8-20-15; 8:45 am]
BILLING CODE 4140-01-P
